<DOC>
	<DOC>NCT01519778</DOC>
	<brief_summary>Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.</brief_summary>
	<brief_title>A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study</brief_title>
	<detailed_description>This is an open-label, multicenter study of oral TR-701 FA 200 mg once daily for 6 days for the treatment of major cutaneous abscess or cellulitis/erysipelas in patients 18 years of age or older. This study is designed to further characterize the safety profile and gather additional lesion measurement data of TR-701 FA in patients with major cutaneous abscess or cellulitis/erysipelas.</detailed_description>
	<mesh_term>Abscess</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Erysipelas</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Male or female patients â‰¥ 18 years of age Suspected or documented grampositive infection from baseline Gram stain or culture. Cellulitis/erysipelas or major cutaneous abscesses at Screening Postsurgical or open wound infections Severe sepsis or septic shock Uncomplicated skin and skin structure infections such as furuncles, minor abscesses (&lt; 75 cm2 or area of suppuration not surrounded by cellulitis/erythema), and impetiginous lesions Infections associated with, or in close proximity to, a prosthetic device Known bacteremia or osteomyelitis at time of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>